As STAT3 is one of the major RTKs’ downstream transcription factors, exploring novel chemotherapeutic agents able to effectively inhibit constitutive as well as inducible activation of STAT3 from multiple stimuli through biochemical modification hold greater potential to reduce cancer mortality. The gene discussed is STAT3; the disease is cancer.